339370-45-5

Basic information

• Product Name: Benzenesulfonyl chloride, 4-(2-methylpropyl)- (9CI)
• Synonyms: Benzenesulfonyl chloride, 4-(2-methylpropyl)- (9CI);4-isobutylbenzenesulfonyl chloride(SALTDATA: FREE);Isobutylbenzenesulfonylchloride;4-(2-methylpropyl)benzenesulfonyl chloride
• CAS NO: 339370-45-5
• Molecular Formula: C₁₀H₁₃ClO₂S
• Molecular Weight: 232.72702
• Product Categories: SULFONYLHALIDE
• Mol File: 339370-45-5.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Benzenesulfonyl chloride, 4-(2-methylpropyl)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenesulfonyl chloride, 4-(2-methylpropyl)- (9CI)(339370-45-5)
• EPA Substance Registry System: Benzenesulfonyl chloride, 4-(2-methylpropyl)- (9CI)(339370-45-5)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 339370-45-5(Hazardous Substances Data)

Usage

General Description

Benzenesulfonyl chloride, 4-(2-methylpropyl)- (9CI) is a chemical compound with the molecular formula C10H13ClO2S. It is a sulfonyl chloride derivative of benzene and contains a 4-(2-methylpropyl) substitution. Benzenesulfonyl chloride, 4-(2-methylpropyl)- (9CI) is used in organic synthesis as a sulfonylating agent, particularly in the synthesis of pharmaceuticals and agrochemicals. It is a reactive and electrophilic compound that can be used as a reagent in the preparation of sulfonamides, sulfonylureas, and other functionalized sulfones. Benzenesulfonyl chloride, 4-(2-methylpropyl)- (9CI) is a versatile and valuable intermediate for the production of various organic compounds in the chemical industry.

Upstream product

• 538-93-2 1-phenyl-2-methylpropane 

Downstream Products

• 1025507-43-0 (R)-N-(1-(1-ethyl-6-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)ethyl)-4-isobutylbenzenesulfonamide 
• 161767-97-1 4-isobutylbenzenesulfonamide 

Relevant articles and documents

CHEMICAL COMPOUNDS

The present disclosure describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the disclosure have activity as Janus kinase (JAK) inhibitors and are useful in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described herein are methods of treating inflammation, auto-immune diseases, cancer, and other conditions susceptible to inhibition of JAK by administering a compound herein described.

Possible anticancer agents: synthesis, pharmacological activity, and molecular modeling studies on some 5-N -Substituted-2-N-(substituted benzenesulphonyl)-L(+)Glutamines

On the basis of our earlier work, fortyone 5-N-substituted-2N-(substituted benzenesulphonyl)-L(+)glutamines were synthesized and screened for cancer cell inhibitory activity. The best active compounds showed 91% tumor cell inhibition, whereas other three compounds showed more than 80% inhibition. Two-dimensional quantitative structure–activity relationship modeling and three-dimensional quantitative structure–activity relationship k-nearest neighbor molecular field analysis studies were done to get an insight into structural requirements toward further improved anticancer activity. Considering the fact that these compounds are competitive inhibitors of glutaminase, a molecular docking study followed by molecular dynamic simulation analysis were performed. The work may help to develop new anticancer agents.

NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF

The present invention provides a novel compound having an agonist action at AT2 receptor and expected as a pharmaceutical product, and also provides a method of treating or preventing various diseases. The novel sulfonyl malonamide derivative,